• Nie Znaleziono Wyników

Vena cava superior stenting for rescue treatment of critical stenosis related to progressing cancer disease

N/A
N/A
Protected

Academic year: 2022

Share "Vena cava superior stenting for rescue treatment of critical stenosis related to progressing cancer disease"

Copied!
1
0
0

Pełen tekst

(1)

www.kardiologiapolska.pl

Kardiologia Polska 2016; 74, 6: 601; DOI: 10.5603/KP.2016.0094 ISSN 0022–9032

Studium przypadku / CliniCal Vignette

Address for correspondence:

Szymon Darocha, MD, Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, ECZ – Otwock, ul. Borowa 14/18, 05–400 Otwock, Poland, e-mail: szymon.darocha@gmail.com

Conflict of interest: none declared

Kardiologia Polska Copyright © Polskie Towarzystwo Kardiologiczne 2016

Vena cava superior stenting for rescue treatment of critical stenosis related to progressing

cancer disease

Stentowanie żyły głównej górnej jako interwencyjne leczenie krytycznego zwężenia u pacjenta z progresją choroby nowotworowej

Szymon Darocha

1

, Sebastian Szmit

1

, Radosław Pietura

2

, Adam Torbicki

1

, Marcin Kurzyna

1

1Department of Pulmonary Circulation and Thromboembolic Diseases, Centre of Postgraduate Medical Education, ECZ – Otwock, Poland

2Department of Radiography, Medical University of Lublin, Lublin, Poland

A 63-year-old female with non-small cell lung cancer (planoepitheliale) in IIIA stadium treated with second-line chemo- therapy, with a history of small-cell lung cancer treated with radical chemo- and radiotherapy in 2007, and a history of breast cancer operated in 2005 was admitted to Department of Pulmonary Circulation and Thromboembolic Diseases with severe vena cava superior (VCS) syndrome. She complained of two weeks’ progression of swelling of the face and neck with mild dysphagia, cough, moderate limitation of movement of the head, blurred vision due to swelling eyeballs, and symptoms of moderate swelling of the brain (headache and dizziness). Computed tomography (CT)-angiography of the chest presented narrowed VCS by surrounding tumour (Fig. 1). The patient was transferred to a cathlab and cavogra- phy was performed presenting critical stenosis of the VCS modelled from outside close to the right atrium (Fig. 2). Using a 12 × 60-mm balloon pre-dilatation of the stricture was performed (Fig. 3). A self-expanding 12 mm × 60-mm SMART Control stent was inserted into the VCS with post-dilatation of a 14 × 40-mm

balloon. VCS syndrome resolved within 2 h after stenting. Control phlebography confirmed normal bilateral blood flow through brachiocephalic veins and the VCS (Fig. 4). The course of the procedure was uneventful and anticoagulant treatment with low molecular weight heparin was continued. The prognosis in cancer patients with VCS syndrome is very poor and depends on histopathologi- cal diagnosis and intensity of clinical symptoms. Percutaneous balloon angioplasty of the VCS with stent implantation is a significantly promising technique, espe- cially in patients with severe symptoms, in whom radiotherapy or chemotherapy cannot reduce the mass of the progressing tumour. Antithrombotic drugs are not effective if the clots are not the main cause of stenosis. The presented patient experienced significant clinical improvement, achieved World Heart Organisa- tion functional class I and was able to continue oncological treatment without any recurrence of VCS syndrome.

Figure 1. Computed tomography-angio - graphy of the chest presented narro- wed vena cava superior by surrounding tumour mass (arrow)

Figure 2. Superior vena cava modelled from the outside by tumour mass (arrow)

Figure 3. Balloon pre-dilatation of the narrowed vessel

Figure 4. Cavography — the final effect of vena cava superior stenting

Cytaty

Powiązane dokumenty

A randomized, double- blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B

A 74-year-old patient, a long-term smoker (50 pack-years), with a previously diagnosed total si- tus inversus, generalised atherosclerosis, arterial hypertension and a history

Średnie przeżycia chorych na niedrobnokomórkowego raka płuca w III stopniu zaawansowania wynoszą według większości autorów około 17 miesięcy, w przypadku cho- roby

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.. Bezpieczeństwo

The most significant prognostic factor in the qualification of the patients with the advanced, non- small cell lung cancer to the palliative treatment is their performance

The results of the analysis make it possible to state that radical radiotherapy applied as the only method of treatment in the group of patients with non-small cell

Treatment with a small-molecule EGFR TKIs is the treatment of choice for patients with metastatic NSCLC with an activating EGFR gene mutation and should be first-line

wykazano, że stosowanie inhibitorów kinazy tyrozynowej (TKI, tyrosine kinase inhibitor) receptora naskórkowego czynnika wzrostu (EGFR, endothelial growth factor re- ceptor)